With FDA Guidance Urging Innovation, Will Novel Smoking Cessation Products Surface In US?
Executive Summary
CDER reiterates expectation for multiple trials to demonstrate efficacy for an IND different from approved products, such as route of administration, for smoking cessation or reduction in risk of relapse. Agency offers access to expedited approval pathways by showing significant improvement in efficacy or safety over existing therapies or addressing unmet medical need.
You may also be interested in...
Nicotine Hits Smokers’ Bloodstreams In Seconds – Clock On Latest US NRT Approval Is At 17 Years
Gum, lozenge and patch NRTs available in US need as much as 30 minutes to deliver nicotine to users’ bloodstreams. Cigarettes are "purposely designed because of inhalation of smoke to deliver nicotine to the receptors in the brain in less than 10 seconds,” says former FDA tobacco programs chief Mitch Zeller.
US Has Pieces For Solving Policy Puzzle To Spur Spread Of Smoking Cessation Products, Programs
Former FDA tobacco programs chief Mitch Zeller says needed is commitment from White House to require reduction in nicotine levels in tobacco products and movement by FDA on finalizing rules prohibiting use of menthol and other flavors in cigarettes and some cigars.
J&J’s Nicorette Becomes World’s First Licensed Vaping And Smoking Cessation Therapy
J&J's OTC nicotene replacemnt therapy brand Nicorette goes from strength to strength in the UK with a world-first approval from the country's medicines regulator for its Quickmist product for vaping cessation.